Unibest
← Back to patent-cliff list

CAS 2044680-91-1

(1aR,1bS,2aS,3aS,6aS,10S,10aS,11aS)-10-[(Benzyloxy)methoxy]-1b,10a,12,12-tetramethyl-2a,3,8,9,10,10a,11,11a-octahydro-1bH,5H,6aH-1a,3a-methanobenzo[3,4]bisoxireno[6,7:8,9]cyclodeca[1,2-d][1,3]dioxol-5-one

Codes: (XVIII)101438-60-b

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
PaclitaxelTier B — Position early-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.